Search research articles
Contact Us
Filters
Showing results (361-370 of 404) with videos related to
Page
of 41
Sort By:
Hepatology International
|
July 24, 2015
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial
Mitchell L Shiffman, Hugo Cheinquer, Christoph P Berg, et al.
The International Journal on Drug Policy
|
March 20, 2026
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study
Anna Conway, Jason Grebely, Shane Tillakeratne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Qinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
The Journal of Infectious Diseases
|
August 31, 2016
Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia
Chaturaka Rodrigo, Auda A Eltahla, Rowena A Bull, et al.
AIDS (London, England)
|
July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infection
Marianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Viruses
|
July 27, 2022
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study
Anna Conway, Heather Valerio, Maryam Alavi, et al.
Page
of 41
Search research articles
Search
Showing results (361-370 of 404) with videos related to
Sort By:
Page
of 41
Hepatology International
|
July 24, 2015
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial
Mitchell L Shiffman, Hugo Cheinquer, Christoph P Berg, et al.
The International Journal on Drug Policy
|
March 20, 2026
Reinfection following direct-acting antiviral therapy for hepatitis C infection among people in prison with recent injecting drug use: the SHARP-P study
Anna Conway, Jason Grebely, Shane Tillakeratne, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Qinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
The Journal of Infectious Diseases
|
August 31, 2016
Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia
Chaturaka Rodrigo, Auda A Eltahla, Rowena A Bull, et al.
AIDS (London, England)
|
July 19, 2023
Reinfection incidence and risk among people treated for recent hepatitis C virus infection
Marianne Martinello, Joanne M Carson, Marc Van Der Valk, et al.
Viruses
|
July 27, 2022
A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study
Anna Conway, Heather Valerio, Maryam Alavi, et al.
Page
of 41